2023-06-012024-05-312024-05-31false072651813H PHARMACIES LTD2025-02-24falseiso4217:GBPxbrli:pure072651812023-06-01072651812024-05-31072651812023-06-012024-05-31072651812022-06-01072651812023-05-31072651812022-06-012023-05-3107265181bus:SmallEntities2023-06-012024-05-3107265181bus:AuditExempt-NoAccountantsReport2023-06-012024-05-3107265181bus:FullAccounts2023-06-012024-05-3107265181bus:PrivateLimitedCompanyLtd2023-06-012024-05-3107265181core:WithinOneYear2024-05-3107265181core:AfterOneYear2024-05-3107265181core:WithinOneYear2023-05-3107265181core:AfterOneYear2023-05-3107265181core:ShareCapital2024-05-3107265181core:SharePremium2024-05-3107265181core:RevaluationReserve2024-05-3107265181core:OtherReservesSubtotal2024-05-3107265181core:RetainedEarningsAccumulatedLosses2024-05-3107265181core:ShareCapital2023-05-3107265181core:SharePremium2023-05-3107265181core:RevaluationReserve2023-05-3107265181core:OtherReservesSubtotal2023-05-3107265181core:RetainedEarningsAccumulatedLosses2023-05-3107265181core:LandBuildings2024-05-3107265181core:PlantMachinery2024-05-3107265181core:Vehicles2024-05-3107265181core:FurnitureFittings2024-05-3107265181core:OfficeEquipment2024-05-3107265181core:NetGoodwill2024-05-3107265181core:IntangibleAssetsOtherThanGoodwill2024-05-3107265181core:ListedExchangeTraded2024-05-3107265181core:UnlistedNon-exchangeTraded2024-05-3107265181core:LandBuildings2023-05-3107265181core:PlantMachinery2023-05-3107265181core:Vehicles2023-05-3107265181core:FurnitureFittings2023-05-3107265181core:OfficeEquipment2023-05-3107265181core:NetGoodwill2023-05-3107265181core:IntangibleAssetsOtherThanGoodwill2023-05-3107265181core:ListedExchangeTraded2023-05-3107265181core:UnlistedNon-exchangeTraded2023-05-3107265181core:LandBuildings2023-06-012024-05-3107265181core:PlantMachinery2023-06-012024-05-3107265181core:Vehicles2023-06-012024-05-3107265181core:FurnitureFittings2023-06-012024-05-3107265181core:OfficeEquipment2023-06-012024-05-3107265181core:NetGoodwill2023-06-012024-05-3107265181core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3107265181core:ListedExchangeTraded2023-06-012024-05-3107265181core:UnlistedNon-exchangeTraded2023-06-012024-05-3107265181core:MoreThanFiveYears2023-06-012024-05-3107265181core:Non-currentFinancialInstruments2024-05-3107265181core:Non-currentFinancialInstruments2023-05-3107265181dpl:CostSales2023-06-012024-05-3107265181dpl:DistributionCosts2023-06-012024-05-3107265181core:LandBuildings2023-06-012024-05-3107265181core:PlantMachinery2023-06-012024-05-3107265181core:Vehicles2023-06-012024-05-3107265181core:FurnitureFittings2023-06-012024-05-3107265181core:OfficeEquipment2023-06-012024-05-3107265181dpl:AdministrativeExpenses2023-06-012024-05-3107265181core:NetGoodwill2023-06-012024-05-3107265181core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3107265181dpl:GroupUndertakings2023-06-012024-05-3107265181dpl:ParticipatingInterests2023-06-012024-05-3107265181dpl:GroupUndertakingscore:ListedExchangeTraded2023-06-012024-05-3107265181core:ListedExchangeTraded2023-06-012024-05-3107265181dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-06-012024-05-3107265181core:UnlistedNon-exchangeTraded2023-06-012024-05-3107265181dpl:CostSales2022-06-012023-05-3107265181dpl:DistributionCosts2022-06-012023-05-3107265181core:LandBuildings2022-06-012023-05-3107265181core:PlantMachinery2022-06-012023-05-3107265181core:Vehicles2022-06-012023-05-3107265181core:FurnitureFittings2022-06-012023-05-3107265181core:OfficeEquipment2022-06-012023-05-3107265181dpl:AdministrativeExpenses2022-06-012023-05-3107265181core:NetGoodwill2022-06-012023-05-3107265181core:IntangibleAssetsOtherThanGoodwill2022-06-012023-05-3107265181dpl:GroupUndertakings2022-06-012023-05-3107265181dpl:ParticipatingInterests2022-06-012023-05-3107265181dpl:GroupUndertakingscore:ListedExchangeTraded2022-06-012023-05-3107265181core:ListedExchangeTraded2022-06-012023-05-3107265181dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-06-012023-05-3107265181core:UnlistedNon-exchangeTraded2022-06-012023-05-3107265181core:NetGoodwill2024-05-3107265181core:IntangibleAssetsOtherThanGoodwill2024-05-3107265181core:LandBuildings2024-05-3107265181core:PlantMachinery2024-05-3107265181core:Vehicles2024-05-3107265181core:FurnitureFittings2024-05-3107265181core:OfficeEquipment2024-05-3107265181core:AfterOneYear2024-05-3107265181core:WithinOneYear2024-05-3107265181core:ListedExchangeTraded2024-05-3107265181core:UnlistedNon-exchangeTraded2024-05-3107265181core:ShareCapital2024-05-3107265181core:SharePremium2024-05-3107265181core:RevaluationReserve2024-05-3107265181core:OtherReservesSubtotal2024-05-3107265181core:RetainedEarningsAccumulatedLosses2024-05-3107265181core:NetGoodwill2023-05-3107265181core:IntangibleAssetsOtherThanGoodwill2023-05-3107265181core:LandBuildings2023-05-3107265181core:PlantMachinery2023-05-3107265181core:Vehicles2023-05-3107265181core:FurnitureFittings2023-05-3107265181core:OfficeEquipment2023-05-3107265181core:AfterOneYear2023-05-3107265181core:WithinOneYear2023-05-3107265181core:ListedExchangeTraded2023-05-3107265181core:UnlistedNon-exchangeTraded2023-05-3107265181core:ShareCapital2023-05-3107265181core:SharePremium2023-05-3107265181core:RevaluationReserve2023-05-3107265181core:OtherReservesSubtotal2023-05-3107265181core:RetainedEarningsAccumulatedLosses2023-05-3107265181core:NetGoodwill2022-06-0107265181core:IntangibleAssetsOtherThanGoodwill2022-06-0107265181core:LandBuildings2022-06-0107265181core:PlantMachinery2022-06-0107265181core:Vehicles2022-06-0107265181core:FurnitureFittings2022-06-0107265181core:OfficeEquipment2022-06-0107265181core:AfterOneYear2022-06-0107265181core:WithinOneYear2022-06-0107265181core:ListedExchangeTraded2022-06-0107265181core:UnlistedNon-exchangeTraded2022-06-0107265181core:ShareCapital2022-06-0107265181core:SharePremium2022-06-0107265181core:RevaluationReserve2022-06-0107265181core:OtherReservesSubtotal2022-06-0107265181core:RetainedEarningsAccumulatedLosses2022-06-0107265181core:AfterOneYear2023-06-012024-05-3107265181core:WithinOneYear2023-06-012024-05-3107265181core:Non-currentFinancialInstrumentscore:CostValuation2023-06-012024-05-3107265181core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-06-012024-05-3107265181core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-06-012024-05-3107265181core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-06-012024-05-3107265181core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-06-012024-05-3107265181core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-06-012024-05-3107265181core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3107265181core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3107265181core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3107265181core:Non-currentFinancialInstrumentscore:CostValuation2024-05-3107265181core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-05-3107265181core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-05-3107265181core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-05-3107265181core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-05-3107265181core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-05-3107265181core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-05-3107265181core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-05-3107265181core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-05-3107265181core:Non-currentFinancialInstrumentscore:CostValuation2023-05-3107265181core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-05-3107265181core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-05-3107265181core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-05-3107265181core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-05-3107265181core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-05-3107265181core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-05-3107265181core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-05-3107265181core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-05-3107265181bus:Director12023-06-012024-05-3107265181core:FurnitureFittingsToolsEquipment2023-05-3107265181core:FurnitureFittingsToolsEquipment2023-06-012024-05-3107265181core:FurnitureFittingsToolsEquipment2024-05-31

3H PHARMACIES LTD

Registered Number
07265181
(England and Wales)

Unaudited Financial Statements for the Year ended
31 May 2024

3H PHARMACIES LTD
Company Information
for the year from 1 June 2023 to 31 May 2024

Director

KAZMI, Syed Zia Hussain

Registered Address

Unit 1 27a All Saints Road
Burton-On-Trent
DE14 3LS

Registered Number

07265181 (England and Wales)
3H PHARMACIES LTD
Balance Sheet as at
31 May 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Intangible assets355,75781,779
Tangible assets416,74515,993
72,50297,772
Current assets
Stocks563,69466,205
Debtors6401,450340,450
Cash at bank and on hand54,75692,863
519,900499,518
Creditors amounts falling due within one year7(553,461)(533,033)
Net current assets (liabilities)(33,561)(33,515)
Total assets less current liabilities38,94164,257
Creditors amounts falling due after one year8-(2,096)
Net assets38,94162,161
Capital and reserves
Called up share capital33
Profit and loss account38,93862,158
Shareholders' funds38,94162,161
The financial statements were approved and authorised for issue by the Director on 24 February 2025, and are signed on its behalf by:
KAZMI, Syed Zia Hussain
Director
Registered Company No. 07265181
3H PHARMACIES LTD
Notes to the Financial Statements
for the year ended 31 May 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Intangible assets
Intangible assets are initially measured at cost. After initial recogninition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. Goodwill is being amortised over its estimated useful life of 10 years.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Plant and machinery25
Fixtures and fittings25
Office Equipment25
Stocks and work in progress
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
2.Average number of employees

20242023
Average number of employees during the year108
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 June 23260,225260,225
At 31 May 24260,225260,225
Amortisation and impairment
At 01 June 23178,446178,446
Charge for year26,02226,022
At 31 May 24204,468204,468
Net book value
At 31 May 2455,75755,757
At 31 May 2381,77981,779
4.Tangible fixed assets

Plant & machinery

Vehicles

Fixtures & fittings

Office Equipment

Total

£££££
Cost or valuation
At 01 June 237,0418,50069,39022,207107,138
Additions--4,8758905,765
At 31 May 247,0418,50074,26523,097112,903
Depreciation and impairment
At 01 June 234,2231,41768,89516,61091,145
Charge for year7051,7719841,5535,013
At 31 May 244,9283,18869,87918,16396,158
Net book value
At 31 May 242,1135,3124,3864,93416,745
At 31 May 232,8187,0834955,59715,993
5.Stocks

2024

2023

££
Finished goods63,69466,205
Total63,69466,205
6.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables250,900249,205
Amounts owed by group undertakings101,09950,099
Other debtors42,34234,707
Prepayments and accrued income7,1096,439
Total401,450340,450
7.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables201,686223,601
Bank borrowings and overdrafts14,14027,746
Amounts owed to related parties39,80219,901
Taxation and social security59,48540,848
Payments received on account119,387133,717
Other creditors95,46167,219
Accrued liabilities and deferred income23,50020,001
Total553,461533,033
8.Creditors: amounts due after one year

2024

2023

££
Bank borrowings and overdrafts-2,096
Total-2,096
9.Related party transactions
At the yearend, Kazmi Bros Ltd owed £101,099 (2023: £50,099) to 3H Pharmacies Ltd. The 3H Pharmacies Ltd owed £39,802 (2023: 19,901) to Kazmi & Sons Ltd. The companies are related as Mr. Syed Kazmi is also the director of these companies.